CTOs on the Move

Golden Sap

www.goldensap.com

 
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.goldensap.com
  • 8 rang Saint-Jean-Baptiste RR 2
    Sainte-Aurí©lie, QC CAN G0M 1M0
  • Phone: 860.289.4053

Executives

Name Title Contact Details

Similar Companies

Pulmocide

Pulmocide is a biotechnology company focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.

SBH Willow Peak

Willow Creek Behavioral Health provides mental health treatment and group therapy in Green Bay, WI. Our hospital provides innovative treatments and 24/7 access to care.

Oncology Pharma

Oncology Pharma, Inc. is a pioneering oncology company dedicated to licensing, developing, manufacturing and commercializing therapeutics. The company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the field of oncology, therapeutics and leadership to identify, negotiate and amalgamate “best in class” research, technologies, therapeutics and delivery mechanisms that are synergistic and collaborative. The goal is to create value, reduce costs and increase the speed of regulatory approval and commercialization of effective and safer cancer drugs.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.

R.D. Laboratories

R.D. Laboratories is a Washington, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.